2079878-75-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-chlorophenyl)-2-nitrocyclohexan-1-one serves as an intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and medicinal compounds. Its unique structure allows for versatile chemical reactions, facilitating the creation of a wide range of therapeutic agents.
Used in Agrochemical Production:
In the agrochemical industry, 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one is utilized as a building block for the production of various agrochemicals. Its incorporation into these products can enhance their effectiveness in pest control and crop protection, thereby supporting agricultural productivity.
Used in Organic Compound Synthesis:
Beyond its applications in pharmaceuticals and agrochemicals, 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one also functions as a key component in the synthesis of other organic compounds. Its presence in these reactions can lead to the formation of specialty chemicals with diverse applications across various industries.
Safety Considerations:
Given the potential toxicity and harmful effects of 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one, it is crucial to handle 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one with care. Proper safety measures should be implemented during its production, storage, and use to minimize risks to human health and the environment.

Upstream product

• 108-94-1 cyclohexanone 
• 286-20-4 cyclohexane-1,2-epoxide 
• 694-80-4 2-bromo-1-chlorobenzene 
• 91393-49-6 2-amino-2-(2-chlorophenyl)cyclohexan-1-one 
• 4883-67-4 2-nitrocyclohexanone 

Downstream Products

• 35211-10-0 norketamine 
• 6740-88-1 ketamine 

Relevant academic research and scientific papers

NMDA receptor antagonist and use thereof

The present invention relates to an NMDA receptor antagonist and use thereof. The NMDA receptor antagonist is a compound as shown in the formula I, and pharmaceutically acceptable salts, enantiomers, diastereoisomers, tautomers, solvates, isotope substitutes, polymorphic substances, prodrugs or metabolites thereof, and in the formula, ring A, ring B and R2 are as described in the specification. The invention also provides pharmaceutical compositions containing the compounds, and applications of the compounds in preparation of drugs for treating or preventing NMDA receptor mediated diseases.

Transition-metal-free α-arylation of nitroketones with diaryliodonium salts for the synthesis of tertiary α-aryl, α-nitro ketones

Transition-metal-free α-arylation of α-nitroketones with diaryliodonium salts has been realized for the first time. As an application of this methodology, a concise synthesis of the clinical drug tiletamine was also achieved via a three-step procedure from 2-nitrocyclohexanone without the isolation of intermediates.

Intermediate compound for synthesizing ketamine and method for synthesizing ketamine

The invention discloses an intermediate compound for synthesizing ketamine, having a chemical structural formula shown in the specification. The intermediate compound is prepared by: (i) reacting o-chlorobromobenzene and lithium alkylide to obtain lithium o-chlorophenyl; (ii) reacting the lithium o-chlorophenyl and cyclohexene oxide under the action of Lewis acid. The intermediate compound may be oxidized, nitrified, nitro-reduced and then amino-methylated to produce ketamine. Compared with existing synthetic methods of ketamine, the method of the invention has simple route, low cost and good operation convenience.

Copper-Assisted Direct Nitration of Cyclic Ketones with Ceric Ammonium Nitrate for the Synthesis of Tertiary α-Nitro-α-substituted Scaffolds

An efficient and direct Cu-assisted nitrating approach to create synthetically valuable and challenging tertiary α-nitro-α-substituted moieties has been developed using ceric ammonium nitrate as a nitrating reagent, oxidant, and Lewis acid. Notably, the commonly used clinical drug ketamine was smoothly synthesized in four steps.